Skip to content
Peptide research

Pemvidutide

Also known as ALT-801
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A dual GLP-1/glucagon receptor agonist (1:1 ratio) for weight loss and fatty liver disease (MASH/MASLD). The human evidence is unusually solid: trials show substantial liver fat reduction and meaningful weight loss, with tolerability varying by trial and dose. Antifibrotic benefit and long-term durability are still preliminary, based on limited Phase 2 data. GI side effects are the main risk, and it is not yet FDA-approved.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Improved non-invasive fibrosis markers in MASH; biopsy-confirmed antifibrotic benefit remains unproven.

    Low

    Biopsy fibrosis endpoint was negative, leaving only surrogate marker evidence, still preliminary.

  • Dramatic liver fat reduction (54.7% at 1.8 mg in MASH; 75.2% in MASLD at 24 weeks)

    High

    Confirmed in a randomized 24-week trial, with up to 75% relative liver fat reduction vs placebo.

  • Clinically meaningful weight loss (up to 7.5% vs 0.2% placebo at 48 weeks in MASH)

    High

    Human RCT data show significant body weight reduction, up to 6.2% at 24 weeks vs placebo.

Evidence limits

Evidence Level
Moderate-Strong Evidence

Pemvidutide has Phase 2b data in MASH (n=212, 48 weeks) and Phase 2 data in MASLD (n=64, 24 weeks), both demonstrating significant efficacy on liver endpoints and weight loss. FDA End-of-Phase 2 meeting completed with alignment on Phase 3 design. The PERFORMA Phase 3 registrational trial is underway.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Personal/family history of MTC

    Absolute

    Dual GLP-1/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.

  • History of pancreatitis

    High

    GLP-1 class effect on pancreatitis risk.

  • Severe gastroparesis

    High

    GLP-1 component slows gastric emptying.

General cautions

  • Pregnancy

    Absolute

    Investigational — no reproductive safety data.

Risk summary(3)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Gastrointestinal adverse events (GLP-1 class effect)

    High
  • Glucagon-mediated effects on blood glucose

    Low
  • Limited Phase 3 data

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.